D. E. Shaw & Co., Inc. Neoleukin Therapeutics, Inc. Transaction History

D. E. Shaw & Co., Inc.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$0.92 - $2.25 $22,362 - $54,690	24,307 Added 14.12%	196,421 $202,000
Q1 2022 May 16, 2022	BUY	$1.72 - $5.23 $187,134 - $569,018	108,799 Added 171.84%	172,114 $324,000
Q4 2021 Feb 14, 2022	BUY	$4.65 - $7.75 $172,775 - $287,959	37,156 Added 142.04%	63,315 $305,000
Q3 2021 Nov 15, 2021	BUY	$6.05 - $9.66 $158,261 - $252,695	26,159 New	26,159 $189,000
Q1 2021 May 17, 2021	SELL	$11.26 - $15.78 $193,018 - $270,500	-17,142 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$10.17 - $14.56 $174,334 - $249,587	17,142 New	17,142 $242,000
Q3 2020 Nov 16, 2020	SELL	$9.68 - $17.01 $319,488 - $561,415	-33,005 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$9.95 - $17.05 $3,492 - $5,984	351 Added 1.07%	33,005 $548,000
Q1 2020 May 15, 2020	SELL	$6.12 - $13.64 $360,204 - $802,809	-58,857 Reduced 64.32%	32,654 $372,000
Q4 2019 Feb 14, 2020	SELL	$2.65 - $12.72 $67,991 - $326,357	-25,657 Reduced 21.9%	91,511 $1.13 Million
Q3 2019 Nov 14, 2019	BUY	$2.33 - $3.76 $273,001 - $440,551	117,168 New	117,168 $334,000

199K

Ticker NLTX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 42,579,900
Description
Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of vario...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.